nach oben

Current Treatment Options in Gastroenterology

Erschienen in:

26.07.2017 | Intractable Disease in the Elderly: When Conventional Therapy Fails (S Katz, Section Editor)

The Present Status of Fecal Microbiota Transplantation and Its Value in the Elderly

verfasst von: Yao-Wen Cheng, MD, Monika Fischer, MD, MSc

Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Opinion Statement

Purpose of Review

This article will review current literature describing fecal microbiota transplantation (FMT) in the treatment of various diseases, and its potential role in elderly patients (age ≥ 65 years).

Recent Findings

Research on FMT has blossomed in the last decade and its pivotal role in the treatment of recurrent Clostridium difficile infection (CDI) has been recognized by the American College of Gastroenterology in the latest guidelines. There is also emerging evidence that FMT may be beneficial in the treatment of severe and/or complicated CDI refractory to medical therapy, resulting in decreased rates of colectomy and mortality. In the elderly, CDI is associated with markedly higher rates of mortality and colectomy; outcomes are even worse when patients have underlying inflammatory bowel disease (IBD). While the majority of patients who receive FMT for CDI are older, only a handful of studies focused specifically on FMT treatment outcomes and safety in this age group. Current data corroborate the efficacy and safety profile of FMT, while also supporting its use for recurrent, severe, and/or complicated CDI in the elderly population.

Summary

FMT is recommended for the treatment of recurrent, severe, and/or complicated CDI in patients older than 65 years of age. It may be prudent to offer FMT earlier in the disease course, possibly after just the second recurrence and for the first episode of severe CDI to avert complications including colectomy and end-organ failure that elderly patients are more prone to developing.

Fujimura KE, Slusher NA, Cabana MD, Lynch SV. Role of the gut microbiota in defining human health. Expert Rev Anti-Infect Ther. 2010;8(4):435–54. doi:10.1586/eri.10.14.PubMedPubMedCentralCrossRef

Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65. doi:http://www.nature.com/nature/journal/v464/n7285/suppinfo/nature08821_S1.html.

Borody TJ, Campbell J. Fecal microbiota transplantation: techniques, applications, and issues. Gastroenterol Clin N Am. 2012;41(4):781–803. doi:10.1016/j.gtc.2012.08.008.CrossRef

Khoruts A, Weingarden AR. Emergence of fecal microbiota transplantation as an approach to repair disrupted microbial gut ecology. Immunol Lett. 2014;162(2 Pt A):77–81. doi:10.1016/j.imlet.2014.07.016.PubMedPubMedCentralCrossRef

Petrof EO, Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology. 2014;146(6):1573–82. doi:10.1053/j.gastro.2014.01.004.PubMedPubMedCentralCrossRef

Youngster I, Mahabamunuge J, Systrom HK, Sauk J, Khalili H, Levin J, et al. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med. 2016;14(1):134. doi:10.1186/s12916-016-0680-9.PubMedPubMedCentralCrossRef

Hecker MT, Obrenovich ME, Cadnum JL, Jencson AL, Jain AK, Ho E, et al. Fecal microbiota transplantation by freeze-dried oral capsules for recurrent Clostridium difficile infection. Open Forum Infect Dis. 2016;3(2) doi:10.1093/ofid/ofw091.

Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Treating Clostridium Difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2011;9(12):1044–9. doi:10.1016/j.cgh.2011.08.014.CrossRef

Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315(2):142–9. doi:10.1001/jama.2015.18098.PubMedCrossRef

10.

Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58 doi:10.1093/cid/ciu135.

11.

Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197(3):435–8. doi:10.1086/525047.PubMedCrossRef

12.

Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010;44(5):354–60. doi:10.1097/MCG.0b013e3181c87e02.PubMed

13.

Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–98.PubMedCrossRef

14.

Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Inf Secur. 2009;58(6):403–10. doi:10.1016/j.jinf.2009.03.010.

15.

Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281–9. doi:10.1016/s1473-3099(11)70374-7.PubMedCrossRef

16.

Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2011;53(10):994–1002. doi:10.1093/cid/cir632.CrossRef

17.

Cammarota G, Masucci L, Ianiro G, Bibbo S, Dinoi G, Costamagna G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41(9):835–43. doi:10.1111/apt.13144.PubMedCrossRef

18.

Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE. Outcome after colectomy for Clostridium difficile colitis. Dis Colon rectum. 2004;47(10):1620–6.

19.

Koss K, Clark MA, Sanders DS, Morton D, Keighley MR, Goh J. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis: Off J Assoc Coloproctol G B Irel. 2006;8(2):149–54. doi:10.1111/j.1463-1318.2005.00876.x.CrossRef

20.

Girotra M, Kumar V, Khan JM, Damisse P, Abraham RR, Aggarwal V, et al. Clinical predictors of fulminant colitis in patients with Clostridium difficile infection. Saudi J Gastroenterol: Off J Saudi Gastroenterol Assoc. 2012;18(2):133–9. doi:10.4103/1319-3767.93820.CrossRef

21.

Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011;254(3):423–427; discussion 7-9. doi:10.1097/SLA.0b013e31822ade48.PubMedCrossRef

22.

Nguyen LBL, Osman M, Chiang AL, Edelstein C, Fischer M, Ananthakrishnan AN, et al. Su1745 the cost-effectiveness of competing strategies for treating severe-complicated Clostridium difficile infection: comparing fecal microbiota transplantation with standard colectomy. Gastroenterology. 150(4):S543. doi:10.1016/S0016-5085(16)31862-5.

23.

•• Agrawal M, Aroniadis OC, Brandt LJ, Kelly C, Freeman S, Surawicz C, et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol. 2016;50(5):403–7. doi:10.1097/mcg.0000000000000410. Largest case series to date on cure rate and safety of FMT in the treatment of CDI in the elderlyPubMed

24.

Aroniadis OC, Brandt LJ, Greenberg A, Borody T, Kelly CR, Mellow M, et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol. 2016;50(5):398–402. doi:10.1097/mcg.0000000000000374.PubMed

25.

•• Fischer M, Sipe BW, Rogers NA, Cook GK, Robb BW, Vuppalanchi R, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015;42(4):470–6. doi:10.1111/apt.13290. Sequential inpatient FMT protocol with great success in the treatment of severe and/or complicated CDIPubMedCrossRef

26.

Fischer M, Sipe B, Cheng YW, Phelps E, Rogers N, Sagi S, et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes. 2016:1–14. doi:10.1080/19490976.2016.1273998.

27.

Cammarota G, Ianiro G, Magalini S, Gasbarrini A, Gui D. Decrease in surgery for Clostridium difficile infection after starting a program to transplant fecal microbiota. Ann Intern Med. 2015;163(6):487–8. doi:10.7326/l15-5139.PubMedCrossRef

28.

Keller JM, Surawicz CM. Clostridium difficile infection in the elderly. Clin Geriatr Med. 2014;30(1):79–93. doi:10.1016/j.cger.2013.10.008.PubMedCrossRef

29.

Napolitano LM, Edmiston CE Jr. Clostridium difficile disease: diagnosis, pathogenesis, and treatment update. Surgery. doi:10.1016/j.surg.2017.01.018.

30.

Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ: Can Med Assoc J. 2005;173(9):1037–42. doi:10.1503/cmaj.050978.CrossRef

31.

Loo VG, Bourgault A-M, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693–703. doi:10.1056/NEJMoa1012413.PubMedCrossRef

32.

Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–54.PubMedCrossRef

33.

Lovat LB. Age related changes in gut physiology and nutritional status. Gut. 1996;38(3):306–9.PubMedPubMedCentralCrossRef

34.

Olsen M, Stwalley D, Demont C, Mahe C, Dubberke ER. Minimal Contribution of Age to Risk of Clostridium difficile Infection in the Elderly. ID Week; October 8, 2015; San Diego, CA 2015.

35.

DePestel DD, Aronoff DM. Epidemiology of Clostridium difficile infection. J Pharm Pract. 2013;26(5):464–75. doi:10.1177/0897190013499521.PubMedPubMedCentralCrossRef

36.

Minino AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. Natl Vital Stat Rep: Cent Dis Control Prev, Natl Cent Health Stat, Natl Vital Stat Syst. 2011;59(10):1–126.

37.

Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009: statistical brief #124. Healthcare cost and utilization project (HCUP) statistical briefs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006.

38.

Kasper AM, Nyazee HA, Yokoe DS, Mayer J, Mangino JE, Khan YM, et al. A multicenter study of Clostridium Difficile infection-related colectomy, 2000-2006. Infect Control Hosp Epidemiol. 2012;33(5):470–6. doi:10.1086/665318.PubMedPubMedCentralCrossRef

39.

Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34(3):346–53. doi:10.1086/338260.PubMedCrossRef

40.

Burke KE, Lamont JT. Fecal transplantation for recurrent Clostridium difficile infection in older adults: a review. J Am Geriatr Soc. 2013;61(8):1394–8. doi:10.1111/jgs.12378.PubMedCrossRef

41.

Girotra M, Garg S, Anand R, Song Y, Dutta SK. Fecal microbiota transplantation for recurrent Clostridium difficile infection in the elderly: long-term outcomes and microbiota changes. Dig Dis Sci. 2016;61(10):3007–15. doi:10.1007/s10620-016-4229-8.PubMedCrossRef

42.

• Li YT, Cai HF, Wang ZH, Xu J, Fang JY. Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Aliment Pharmacol Ther. 2016;43(4):445–57. doi:10.1111/apt.13492. A meta-analysis of FMT efficacy for the treatment of CDI when comparing elderly and non-elderlyPubMedCrossRef

43.

Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146(6):1489–99. doi:10.1053/j.gastro.2014.02.009.PubMedPubMedCentralCrossRef

44.

Gevers D, Kugathasan S, Denson LA, Vazquez-Baeza Y, Van Treuren W, Ren B, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014;15(3):382–92. doi:10.1016/j.chom.2014.02.005.PubMedPubMedCentralCrossRef

45.

Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36(6):503–16. doi:10.1111/j.1365-2036.2012.05220.x.PubMedCrossRef

46.

Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, et al. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohn's Colitis. 2016;10(4):387–94. doi:10.1093/ecco-jcc/jjv203.CrossRef

47.

Vaughn BP, Vatanen T, Allegretti JR, Bai A, Xavier RJ, Korzenik J, et al. Increased intestinal microbial diversity following fecal microbiota transplant for active Crohn’s disease. Inflamm Bowel Dis. 2016;22(9):2182–90. doi:10.1097/mib.0000000000000893.PubMedCrossRef

48.

Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 149(1):102-9.e6. doi:10.1053/j.gastro.2015.04.001.

49.

Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet (London, England). 2017;389(10075):1218–28. doi:10.1016/s0140-6736(17)30182-4.CrossRef

50.

Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149(1):110-8.e4. doi:10.1053/j.gastro.2015.03.045.CrossRef

51.

Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol. 2016;13(9):508–16. doi:10.1038/nrgastro.2016.98.PubMedCrossRef

52.

Robertson DJ, Grimm IS. Inflammatory bowel disease in the elderly. Gastroenterol Clin N Am. 2001;30(2):409–26.CrossRef

53.

Zimmerman J, Gavish D, Rachmilewitz D. Early and late onset ulcerative colitis: distinct clinical features. J Clin Gastroenterol. 1985;7(6):492–8.PubMedCrossRef

54.

Riegler G, Tartaglione MT, Carratu R, D'Inca R, Valpiani D, Russo MI, et al. Age-related clinical severity at diagnosis in 1705 patients with ulcerative colitis: a study by GISC (Italian Colon-rectum study group). Dig Dis Sci. 2000;45(3):462–5.PubMedCrossRef

55.

Wagtmans MJ, Verspaget HW, Lamers CB, van Hogezand RA. Crohn’s disease in the elderly: a comparison with young adults. J Clin Gastroenterol. 1998;27(2):129–33.PubMedCrossRef

56.

Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8(4):244–50.PubMedCrossRef

57.

Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996;31(3):260–6.PubMedCrossRef

58.

Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008;135(4):1106–13. doi:10.1053/j.gastro.2008.06.079.PubMedCrossRef

59.

Ananthakrishnan AN, Binion DG. Treatment of ulcerative colitis in the elderly. Dig Dis (Basel, Switzerland). 2009;27(3):327–34. doi:10.1159/000228569.CrossRef

60.

• Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009;15(2):182–9. doi:10.1002/ibd.20628. Epidemiologic study demonstrating significantly worse outcomes in elderly hospitalized with IBD compared to younger counterpartsPubMedCrossRef

61.

Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol. 2011;106(11):1889–97. doi:10.1038/ajg.2011.271.PubMedCrossRef

62.

Hajjar ER, Hanlon JT, Sloane RJ, Lindblad CI, Pieper CF, Ruby CM, et al. Unnecessary drug use in frail older people at hospital discharge. J Am Geriatr Soc. 2005;53(9):1518–23. doi:10.1111/j.1532-5415.2005.53523.x.PubMedCrossRef

63.

Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001;38(6):666–71. doi:10.1067/mem.2001.119456.PubMedCrossRef

64.

Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(6):1443–50. doi:10.1111/j.1572-0241.2007.01780.x.PubMedCrossRef

65.

Hourigan SK, Oliva-Hemker M, Hutfless S. The prevalence of Clostridium difficile infection in pediatric and adult patients with inflammatory bowel disease. Dig Dis Sci. 2014;59(9):2222–7. doi:10.1007/s10620-014-3169-4.PubMedCrossRef

66.

Binion DG. Clostridium difficile infection in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2012;8(9):615–7.

67.

Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(4):976–83. doi:10.1002/ibd.21457.PubMedCrossRef

68.

Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57(2):205–10. doi:10.1136/gut.2007.128231.PubMedCrossRef

69.

Jen MH, Saxena S, Bottle A, Aylin P, Pollok RC. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33(12):1322–31. doi:10.1111/j.1365-2036.2011.04661.x.PubMedCrossRef

70.

Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109(7):1065–71. doi:10.1038/ajg.2014.133.PubMedPubMedCentralCrossRef

71.

Khoruts A, Rank KM, Newman KM, Viskocil K, Vaughn BP, Hamilton MJ, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol : Off Clin Pract J Am Gastroenterol Assoc. 2016;14(10):1433–8. doi:10.1016/j.cgh.2016.02.018.CrossRef

72.

• Fischer M, Kao D, Kelly C, Kuchipudi A, Jafri SM, Blumenkehl M, et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(10):2402–9. doi:10.1097/mib.0000000000000908. Large case series describing efficacy and subsequent IBD disease course after treatment of CDI with FMT in patients with underlying IBDPubMedCrossRef

73.

Cohen NA, Maharshak N. Novel indications for fecal microbial transplantation: update and review of the literature. Dig Dis Sci. 2017:1–15. doi:10.1007/s10620-017-4535-9.

74.

Panda S, Guarner F, Manichanh C. Structure and functions of the gut microbiome. Endocr Metab Immune Disord Drug Targets. 2014;14(4):290–9.PubMedCrossRef

75.

Brown JM, Hazen SL. The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu Rev Med. 2015;66:343–59. doi:10.1146/annurev-med-060513-093205.PubMedPubMedCentralCrossRef

76.

Kriegel MA, Sefik E, Hill JA, Wu HJ, Benoist C, Mathis D. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2011;108(28):11548–53. doi:10.1073/pnas.1108924108.PubMedPubMedCentralCrossRef

77.

Scher JU, Littman DR, Abramson SB. Microbiome in inflammatory arthritis and human rheumatic diseases. Arthritis Rheumatol (Hoboken, NJ). 2016;68(1):35–45. doi:10.1002/art.39259.CrossRef

78.

Ochoa-Reparaz J, Mielcarz DW, Ditrio LE, Burroughs AR, Foureau DM, Haque-Begum S, et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol (Baltimore, Md : 1950). 2009;183(10):6041–50. doi:10.4049/jimmunol.0900747.CrossRef

79.

Shen L, Liu L, Ji HF. Alzheimer’s disease histological and behavioral manifestations in transgenic mice correlate with specific gut microbiome state. J Alzheimers Dis. 2017;56(1):385–90. doi:10.3233/jad-160884.PubMedCrossRef

80.

Mirza A, Mao-Draayer Y. The gut microbiome and microbial translocation in multiple sclerosis. Clin Immunol (Orlando, Fla). 2017; doi:10.1016/j.clim.2017.03.001.

81.

Bercik P, Wang L, Verdu EF, Mao YK, Blennerhassett P, Khan WI, et al. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology. 2004;127(1):179–87.PubMedCrossRef

82.

Ringel Y, Maharshak N. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2013;305(8):G529–41. doi:10.1152/ajpgi.00207.2012.PubMedPubMedCentralCrossRef

83.

Andrews P, Borody T, Shortis N, Thompson S. Bacteriotherapy for chronic constipation - a long term follow-up. Gastroenterology. 108(4):A563. doi:10.1016/0016-5085(95)26563-5.

84.

Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experience. Am J Gastroenterol. 2014;109(11):1831–2. doi:10.1038/ajg.2014.295.PubMedCrossRef

85.

Gionchetti P, Calabrese C, Lauri A, Rizzello F. The therapeutic potential of antibiotics and probiotics in the treatment of pouchitis. Expert Rev Gastroenterol Hepatol. 2015;9(9):1175–81. doi:10.1586/17474124.2015.1072046.PubMedCrossRef

86.

El-Nachef N, Lucey K, Somsouk M, Ma A, Bethke M, Leon K, et al. Su1747 fecal microbiota transplant improves symptoms in patients with pouchitis and induces changes in the microbiome: preliminary results of an open label trial. Gastroenterology. 150(4):S544. doi:10.1016/S0016-5085(16)31864-9.

87.

Stallmach A, Lange K, Buening J, Sina C, Vital M, Pieper DH. Fecal microbiota transfer in patients with chronic antibiotic-refractory pouchitis. Am J Gastroenterol. 2016;111(3):441–3. doi:10.1038/ajg.2015.436.PubMedCrossRef

88.

Fang S, Kraft CS, Dhere T, Srinivasan J, Begley B, Weinstein D, et al. Successful treatment of chronic Pouchitis utilizing fecal microbiota transplantation (FMT): a case report. Int J Color Dis. 2016;31(5):1093–4. doi:10.1007/s00384-015-2428-y.CrossRef

89.

Gerard P. Gut microbiota and obesity. Cell Mol Life Sci. 2016;73(1):147–62. doi:10.1007/s00018-015-2061-5.PubMedCrossRef

90.

Greenblum S, Turnbaugh PJ, Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci U S A. 2012;109(2):594–9. doi:10.1073/pnas.1116053109.PubMedCrossRef

91.

Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Asp Med. 2013;34(1):39–58. doi:10.1016/j.mam.2012.11.001.CrossRef

92.

Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913-6.e7. doi:10.1053/j.gastro.2012.06.031.PubMedCrossRef

93.

Fischer M, Sipe B, Torbeck M, Xu H, Kassam Z, Allegretti JR. Does fecal microbiota transplantation from an obese donor lead to weight gain? A case series of 70 recipients. Gastroenterology. 152(5):S1004. doi:10.1016/S0016-5085(17)33408-X.

94.

Kao D, Roach B, Park H, Hotte N, Madsen K, Bain V, et al. Fecal microbiota transplantation in the management of hepatic encephalopathy. Hepatology (Baltimore, Md). 2016;63(1):339–40. doi:10.1002/hep.28121.CrossRef

95.

Ren YD, Ye ZS, Yang LZ, Jin LX, Wei WJ, Deng YY, et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy. Hepatology (Baltimore, Md). 2016; doi:10.1002/hep.29008.

96.

Kakihana K, Fujioka Y, Suda W, Najima Y, Kuwata G, Sasajima S, et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood. 2016;128(16):2083–8. doi:10.1182/blood-2016-05-717652.PubMedPubMedCentralCrossRef

97.

Borody T, Leis S, Campbell J, Torres M, Nowak A. Fecal microbiota transplantation (FMT) in multiple sclerosis (MS). Am J Gastroenterol. 2011;106:S352.

98.

Borody T, Nowak A, Torres M, Campbell J, Finlayson S, Leis S. Bacteriotherapy in chronic fatigue syndrome (CFS): a retrospective review. Am J Gastroenterol. 2012;107:S591–2.

99.

Chan AO, Lee LN, Chan AC, Ho WN, Chan QW, Lau S, et al. Predictive factors for colonoscopy complications. Hong Kong Med J = Xianggang yi xue za zhi. 2015;21(1):23–9. doi:10.12809/hkmj144266.

100.

Jentschura D, Raute M, Winter J, Henkel T, Kraus M, Manegold BC. Complications in endoscopy of the lower gastrointestinal tract. Ther Prognosis Surg Endosc. 1994;8(6):672–6.CrossRef

101.

Iqbal CW, Chun YS, Farley DR. Colonoscopic perforations: a retrospective review. J Gastrointest Surg: Off J Soc Surg Alimentary Tract. 2005;9(9):1229–1235: discussion 36. doi:10.1016/j.gassur.2005.06.023.CrossRef

102.

Anderson ML, Pasha TM, Leighton JA. Endoscopic perforation of the colon: lessons from a 10-year study. Am J Gastroenterol. 2000;95(12):3418–22. doi:10.1111/j.1572-0241.2000.03356.x.PubMedCrossRef

103.

Korman LY, Overholt BF, Box T, Winker CK. Perforation during colonoscopy in endoscopic ambulatory surgical centers. Gastrointest Endosc. 2003;58(4):554–7.PubMedCrossRef

104.

Waye JD, Lewis BS, Yessayan S. Colonoscopy: a prospective report of complications. J Clin Gastroenterol. 1992;15(4):347–51.PubMedCrossRef

105.

Levin TR, Zhao W, Conell C, Seeff LC, Manninen DL, Shapiro JA, et al. Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med. 2006;145(12):880–6.PubMedCrossRef

106.

Ghazi A, Grossman M. Complications of colonoscopy and polypectomy. Surg Clin North Am. 1982;62(5):889–96.PubMedCrossRef

107.

DiPrima RE, Barkin JS, Blinder M, Goldberg RI, Phillips RS. Age as a risk factor in colonoscopy: fact versus fiction. Am J Gastroenterol. 1988;83(2):123–5.PubMed

108.

Karajeh MA, Sanders DS, Hurlstone DP. Colonoscopy in elderly people is a safe procedure with a high diagnostic yield: a prospective comparative study of 2000 patients. Endoscopy. 2006;38(3):226–30. doi:10.1055/s-2005-921209.PubMedCrossRef

109.

Arora A, Singh P. Colonoscopy in patients 80 years of age and older is safe, with high success rate and diagnostic yield. Gastrointest Endosc. 2004;60(3):408–13.PubMedCrossRef

110.

Hamdani U, Naeem R, Haider F, Bansal P, Komar M, Diehl DL, et al. Risk factors for colonoscopic perforation: a population-based study of 80118 cases. World J Gastroenterol. 2013;19(23):3596–601. doi:10.3748/wjg.v19.i23.3596.PubMedPubMedCentralCrossRef

111.

Arora G, Mannalithara A, Singh G, Gerson LB, Triadafilopoulos G. Risk of perforation from a colonoscopy in adults: a large population-based study. Gastrointest Endosc. 2009;69(3 Pt 2):654–64. doi:10.1016/j.gie.2008.09.008.PubMedCrossRef

112.

Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst. 2003;95(3):230–6.PubMedCrossRef

113.

Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, et al. Systematic review: adverse events of fecal microbiota transplantation. PLoS One. 2016;11(8):e0161174. doi:10.1371/journal.pone.0161174.PubMedPubMedCentralCrossRef

114.

Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the literature. J Hosp Infect. 2016;92(2):117–27. doi:10.1016/j.jhin.2015.10.024.PubMedCrossRef

115.

Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107(5):761–7. doi:10.1038/ajg.2011.482.PubMedCrossRef

116.

Osman M, O'Brien K, Stoltzner Z, Ling K, Koelsch E, Dubois N, et al. Safety and efficacy of fecal microbiota transplantation for recurrent clostridium difficile infection from an international public stool bank: results from a 2050-patient multicenter cohort. Open Forum Infect Dis. 2016;3(suppl_1):2120. doi:10.1093/ofid/ofw172.1668.

117.

Gweon TG, Kim J, Lim CH, Park JM, Lee DG, Lee IS, et al. Fecal microbiota transplantation using upper gastrointestinal tract for the treatment of refractory or severe complicated Clostridium difficile infection in elderly patients in poor medical condition: the first study in an Asian country. Gastroenterol Res Pract. 2016;2016:2687605. doi:10.1155/2016/2687605.PubMedPubMedCentral

118.

Ben-Amor K, Heilig H, Smidt H, Vaughan EE, Abee T, de Vos WM. Genetic diversity of viable, injured, and dead fecal bacteria assessed by fluorescence-activated cell sorting and 16S rRNA gene analysis. Appl Environ Microbiol. 2005;71(8):4679–89. doi:10.1128/aem.71.8.4679-4689.2005.PubMedPubMedCentralCrossRef

119.

Choi HH, Cho YS. Fecal microbiota transplantation: current applications, effectiveness, and future perspectives. Clin Endosc. 2016;49(3):257–65. doi:10.5946/ce.2015.117.PubMedPubMedCentralCrossRef

120.

Chehoud C, Dryga A, Hwang Y, Nagy-Szakal D, Hollister EB, Luna RA, et al. Transfer of viral communities between human individuals during fecal microbiota transplantation. MBio. 2016;7(2):e00322. doi:10.1128/mBio.00322-16.PubMedPubMedCentralCrossRef

121.

Kelly CR, Kim AM, Laine L, Wu GD. The AGA’s fecal microbiota transplantation National Registry: an important step toward understanding risks and benefits of microbiota therapeutics. Gastroenterology. 2017;152(4):681–4. doi:10.1053/j.gastro.2017.01.028.PubMedCrossRef

Titel: The Present Status of Fecal Microbiota Transplantation and Its Value in the Elderly
verfasst von: Yao-Wen Cheng, MD
Monika Fischer, MD, MSc
Publikationsdatum: 26.07.2017
Verlag: Springer US
Erschienen in: Current Treatment Options in Gastroenterology / Ausgabe 3/2017
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-017-0143-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The Present Status of Fecal Microbiota Transplantation and Its Value in the Elderly

Opinion Statement

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Opinion Statement

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Endoscopic Palliation of Pancreatic Cancer

Quality Indicators in Colonoscopy

Dysphagia in the Elderly

Intractable Constipation in the Elderly

Endoscopic Surveillance in Long-standing Colitis

Endoscopic Stents for the Biliary Tree and Pancreas

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin